SEED Therapeutics Inc. has announced that its molecular glue therapy, ST-01156, has been granted Rare Pediatric Disease and ...

The field of cancer treatment is witnessing rapid advancements due to progress in proteomics, genomics, and drug discovery. These technologies have ...

In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a ...

The human genome encodes potentially thousands of tiny proteins that were previously overlooked. The search is on to find out ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...

Oral Macromolecular Formulation Market To Expand At A 5.2% CAGR To Reach A Valuation Of US$ 31.7 Million By 2034 Explore the Pharmaceutical market's evolution in oral macromolecular drug formulations, ...

Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

Northwestern Medicine investigators have discovered a novel mechanism that recognizes and eliminates "bad" transcriptional ...

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.